Interleukin-4 antagonism

IL-4 receptor (IL-4R) is potentially a safe and effective treatment for ast hma without the use of corticosteroids. Once-weekly inhaled dosing targetin g the lungs will likely improve patient compliance, one of the greatest cha llenges facing the effective treatment of asthma. By inhibiting inflammatio n at a key central regulatory point and by treating the underlying cause of asthma, IL-4R may influence long-term disease progression. Additional stud ies of IL-4R are ongoing. Soluble IL-4R therapy revolutionizes our understa nding of asthma and represents the next generation of asthma therapy.